• Skip to primary navigation
  • Skip to main content
  • Skip to footer
MotherToBaby

MotherToBaby

Medications and More during pregnancy and breastfeeding

Hide Search
Show Search
866.626.6847
  • About
    • Our Work
    • Our Team
    • Our Partners
  • Exposures
    • Pregnancy & Breastfeeding Exposures
    • Fact Sheets
    • Baby Blogs
    • Podcasts
  • Studies
    • Ongoing Studies
    • Pregnant Women
    • Join Now
    • Health Providers
    • Pharma Industry
    • Publications
  • Health Professionals
    • Patient Education and Provider Resources
    • Refer a Patient
    • Request Materials
    • Meetings
    • FAQs
    • OTIS Membership
  • Media
    • Press Releases
    • Media Requests
  • In Your Area
  • OTIS
    • About OTIS
    • OTIS Membership
    • Annual Meeting
    • Member Log-In
    • Donate
  • Contact

Mirtazapine (Remeron®)

July 1, 2019

Selected References:

  • Biswas PN, et al. 2003. The pharmacovigilance of mirtazapine: results of a prescription event monitoring study on 13,554 patients in England. J Psychopharmacol 17:121-6.
  • Djulus J, et al. 2006. Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes. J Clin Psychiatry 67(8):1280-4.
  • Einarson A, et al. 2009. Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study. Can J Psychiatry 54(4): 242-246.
  • Grigoriadis S, Vonderporten EH, Mamisashvili L, Eady A, Tomlinson G, Dennis CL, Koren G, Steiner M, Mousmanis P, Cheung A, Ross LE. The effect of prenatal antidepressant exposure on neonatal adaptation: a systematic review and meta-analysis. J Clin Psychiatry. 2013;74(4):e309-20.
  • Guclu S, et al. 2005. Mirtazapine use in resistant hyperemesis gravidarum: report of three cases and review of the literature. Arch Gynecol Obstet 272(4):298-300
  • Kieviet N, et al. 2015. Risk factors for poor neonatal adaptation after exposure to antidepressants in utero. Acta Paediatr. 104(4):384-91.
  • Kjaersgaard MI, et al. 2013. Prenatal antidepressant exposure and risk of spontaneous abortion – a population-based study. PLoS One. 8(8):e72095.
  • Klier C, et al. 2007. Mirtazapine and breastfeeding: maternal and infant plasma levels. Am J Pyschiatry 164:2: 348-349.
  • Kristensen JH, et al. 2007. Transfer of the antidepressant mirtazapine into breast milk. Br J Clin Pharmacol 63:322-7.
  • Lennestal R. 2007. Delivery outcome in relation to maternal use of some recently introduced antidepressants. J Clin Psyhcopharmacology 27(6):607-613.
  • Saks BR. 2001. Mirtazapine: treatment of depression, anxiety, and hyperemesis gravidarum in the pregnant patient: A report of 7 cases. Arch Womens Ment Health  3(4):165-170.
  • Schwarzer V, et al. 2008. Treatment resistant hyperemesis gravidarum in a patient with type I diabetes mellitus: neonatal withdrawl symptoms after successful antiemetic therapy with mirtazapine. Arch Gynecol Obstet 277:67-69.
  • Smit M, et al. 2016. Mirtazapine in pregnancy and lactation: A systemic review. European Neuropsychoparmacology. 26: 126-135.
  • Smit M, et al. 2015 Mirtazapine in pregnancy and lactation: Data from a case series. J Clin Psychopharmacol. 35:163-7. Sokolover N, et al. 2008. Neonatal recurrent prolonged hypothermia associated with maternal miratazapine treatment during pregnancy. Can J Clin Pharmacol. 15(2):e188-190.
  • Tonn P, et al. 2009. High mirtazapine plasma levels in infant after breastfeeding: case report and review of the literature. J Clin Psychopharmacol 29(2):191-192.
  • Winterfeld U, et al. 2015. Pregnancy outcome following maternal exposure to mirtazapine: a multicenter, prospective study. J Clin Psychopharmacol. 35(3):25

Footer

           

Hot Links

  • Home
  • Exposures
  • Fact Sheets
  • Baby Blogs
  • Podcasts
  • Pregnancy Studies
  • Join a Study Now
  • Healthcare Professionals
  • Refer a Patient
  • Request Materials
  • News
  • Donate
  • Ask An Expert

Current Studies

  • Ankylosing Spondylitis
  • Asthma
  • Coronavirus (COVID-19)
  • Crohn’s Disease
  • Eczema (Moderate-to-Severe)/Atopic Dermatitis
  • Juvenile Idiopathic Arthritis
  • Multiple Sclerosis
  • Pertussis/Tdap vaccine (“Whopping Cough” vaccine)
  • Psoriasis
  • Psoriatic Arthritis
  • Rheumatoid Arthritis
  • Ulcerative Colitis

Contact

Exposure Information Service
866.626.6847

Pregnancy Studies
877.311.8972

Media Inquiries
615.349.3082
contactus@mothertobaby.org

MotherToBaby, a service of the Organization of Teratology Information Specialists
OTIS Logo

OTIS National Office
5034A Thoroughbred Lane
Brentwood, TN 37027

Copyright © 2021 The Organization of Teratology Information Specialists

  • Accessibility
  • Privacy
  • Terms
  • Site Map
^